Vascular Perfusion Solutions, Inc launched novel Visionary VP.S Encore™ Cardiac Transport Device. With the use of this patent-pending technology oxygen can be enabled to preserve vascularised tissue for eight hours and more, doubling the possibility of organs beyond the current standard of care. VP.S Encore™ being a self-contained portable device easily fits in the compartment of a commercial airliner.
Initially the VP.S Encore™ device is determined on heart transport, later on it will be extended to other organs, following lungs, livers and kidneys. In addition, it will also include a platform for future uses, such as skin growth for burn victims.
In the US, more than 10,000 men, women and children have registered new cases and are on waiting list to receive an organ transplant. More than half of the donated organs were rejected since they couldn’t reach to patients in time.
The US Food and Drug Administration (FDA) grants Breakthrough Device Designation for Visionary VP.S Encore™ Cardiac Transport Device.
